Location Based Technologies Inc. (LBAS)
Location Based Technologies Inc. has invested extensive time and resources to develop its own proprietary hardware and software, including a fully integrated and seamless PocketFinder Network System for its PocketFinder® family of products. The Company's customized location solutions provide peace of mind for those who need to know where high-value mobile assets or loved ones are at any time.
Leveraging Global Positioning System (GPS) satellites and existing wireless Global Systems Mobile (GSM) and General Packet Radio Service (GPRS) technologies, Location Based Technologies can help customers locate almost anyone or anything – even inside of a building/structure. Because the Company controls all elements of its location system, they are able to push back traditional barriers of size, battery life and cost for location solutions.
Location Based Technologies focuses on providing top quality products at a "great value" price while maintaining profitability. With their products, parents and caregivers enjoy peace of mind knowing they can locate their loved ones, while businesses can benefit by saving money, securing valuables, reducing inefficiency and becoming more environmentally friendly. The Company stands out by bringing innovative technology to consumers and businesses in a user friendly way.
In most recent news, Location Based Technologies announced a $1.2 million purchase order from a GPS solutions provider for the B2B mobile electronics market in Mexico. The Company anticipates fulfilling the order before the end of this year. According to CEO Dave Morse, this purchase order establishes Location Based Technologies' initial push into the Latin America Market and the Company is very excited about the opportunity Mexico represents.
Sauer Energy Inc. (SENY)
Sauer Energy, Inc. is focused on providing clean energy technology without harming or polluting our environment. Specializing in wind power solutions, the company designs products for commercial use so that urban areas can take advantage of the cost-saving alternative energy options. Sauer Energy manufactures innovative small wind turbine systems that can be roof mounted on homes or small buildings.
The wind energy market has been dominated by horizontal wind turbines, which require significant space and a high level of wind speed – two factors that prevent many companies from taking advantage of the eco-friendly energy source. The company's vertical-axis wind turbine (VAWT) changes the game by featuring minimum blade speed threshold, limited noise pollution, curtailed bird endangerment and flexible space requirements.
Sauer Energy's VAWT systems can be produced and manufactured on a large scale in fabrication factories throughout the world. The design of Sauer Energy's VAWT systems allows for operation in any direction of wind flow and eliminates the weight and gear box, providing more efficient production of energy. The systems also enable maximum extraction at its base and can withstand a higher degree of harsh environmental conditions.
Sauer Energy recently announced that it is now accepting distributorship applications. The Company plans to first target the U.S. market through national distributorships and then ramp up production to begin capitalizing on global demand. Certified distributors will provide consumers and small businesses with full service and maintenance. With several patents in place, Sauer Energy anticipates engaging in manufacturing and commercialization this fall.
Titan Pharmaceuticals, Inc. (TTNP)
Titan Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of products designed to treat central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt (iloperidone), is an atypical antipsychotic approved in the U.S. for the treatment of schizophrenia in adult patients.
Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid (pain medication) dependence. A novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment, this product has shown strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction.
On Wednesday, Titan Pharmaceuticals announced that the U.S. FDA confirmed a Pre-New Drug Application (Pre-NDA) meeting regarding Probuphine. At the meeting, which is to take place October 25, 2011, Titan will review all elements of its Probuphine development program and seek FDA input and guidance on the proposed content of a New Drug Application (NDA). In preparation, the Company will send a comprehensive briefing document including all the data from non-clinical and clinical studies.
"This is an important meeting with the FDA to review all of the information on Probuphine development, especially the robust Phase 3 clinical results of Probuphine in the treatment of opioid addiction. We also expect to discuss and reach agreement with the FDA on the content and data required for the NDA," said Katherine L. Beebe, Ph.D., Executive Vice President and Chief Development Officer of Titan.